Angelo Paolo Dei Tos

Angelo Paolo Dei Tos

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Angelo Paolo Dei Tos

Surgical Pathology and Cytopathology Unit, Department of Medicine, University of Padua School of Medicine, Padua, Italy

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2020 in Nature
Verified
Journal Article
Open access
PDF file
Taobo HuTaobo Hu
Taobo Hu
LALauri A. Aaltonen
Lauri A. Aaltonen
FAFederico Abascal
Federico Abascal
AAAdam Abeshouse
Adam Abeshouse
HAHiroyuki Aburatani
Hiroyuki Aburatani
CMChristian von Mering
Christian von Mering
Cancer is driven by genetic change, and the advent of massively parallel sequencing has enabled systematic documentation of this variation at the whole-genome scale1–3. Here we report the integrative analysis of 2,658 whole-cancer genomes and their matching normal tissues across 38 tumour types from the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA). We describe the generation of the PCAWG resource, facilitated by international data sharing using compute clouds. On average, cancer genomes contained 4–5 driver mutations when combining coding and non-coding genomic elements; however, in around 5% of cases no drivers were identified, suggesting that cancer driver discovery is not yet complete. Chromothripsis, in which many clustered structural variants arise in a single catastrophic event, is frequently an early event in tumour evolution; in acral melanoma, for example, these events precede most somatic point mutations and affect several cancer-associated genes simultaneously. Cancers with abnormal telomere maintenance often originate from tissues with low replicative activity and show several mechanisms of preventing telomere attrition to critical levels. Common and rare germline variants affect patterns of somatic mutation, including point mutations, structural variants and somatic retrotransposition. A collection of papers from the PCAWG Consortium describes non-coding mutations that drive cancer beyond those in the TERT promoter4; identifies new signatures of mutational processes that cause base substitutions, small insertions and deletions and structural variation5,6; analyses timings and patterns of tumour evolution7; describes the diverse transcriptional consequences of somatic mutation on splicing, expression levels, fusion genes and promoter activity8,9; and evaluates a range of more-specialized features of cancer genomes8,10–18.

1 May 2012 in The Lancet
Verified
Journal Article
Closed access
WGWinette Ta van der Graaf
Winette Ta van der Graaf
Jaen-Yves BlayJaen-Yves Blay
Jaen-Yves Blay
SCSant P Chawla
Sant P Chawla
DKDong-Wan Kim
Dong-Wan Kim
BBBinh Bui-Nguyen
Binh Bui-Nguyen
PHPeter Hohenberger
Peter Hohenberger

1 November 2020 in Pathologica
Verified
Journal Article
Open access
PDF file
MSMarta Sbaraglia
Marta Sbaraglia
EBElena Bellan
Elena Bellan
ATAngelo Paolo Dei Tos
Angelo Paolo Dei Tos
Mesenchymal tumours represent one of the most challenging field of diagnostic pathology and refinement of classification schemes plays a key role in improving the quality of pathologic diagnosis and, as a consequence, of therapeutic options. The recent publication of the new WHO classification of Soft Tissue Tumours and Bone represents a major step toward improved standardization of diagnosis. Importantly, the 2020 WHO classification has been opened to expert clinicians that have further contributed to underline the key value of pathologic diagnosis as a rationale for proper treatment. Several relevant advances have been introduced. In the attempt to improve the prediction of clinical behaviour of solitary fibrous tumour, a risk assessment scheme has been implemented. NTRK-rearranged soft tissue tumours are now listed as an “emerging entity” also in consideration of the recent therapeutic developments in terms of NTRK inhibition. This decision has been source of a passionate debate regarding the definition of “tumour entity” as well as the consequences of a “pathology agnostic” approach to precision oncology. In consideration of their distinct clinicopathologic features, undifferentiated round cell sarcomas are now kept separate from Ewing sarcoma and subclassified, according to the underlying gene rearrangements, into three main subgroups (CIC, BCLR and not ETS fused sarcomas) Importantly, In order to avoid potential confusion, tumour entities such as gastrointestinal stroma tumours are addressed homogenously across the different WHO fascicles. Pathologic diagnosis represents the integration of morphologic, immunohistochemical and molecular characteristics and is a key element of clinical decision making. The WHO classification is as a key instrument to promote multidisciplinarity, stimulating pathologists, geneticists and clinicians to join efforts aimed to translate novel pathologic findings into more effective treatments.

1 April 2014 in The Lancet Oncology
Verified
Journal Article
Closed access
IJIan Judson
Ian Judson
JVJaap Verweij
Jaap Verweij
HGHans Gelderblom
Hans Gelderblom
JHJörg T Hartmann
Jörg T Hartmann
PSPatrick Schöffski
Patrick Schöffski
WGWinette T A van der Graaf
Winette T A van der Graaf

15 February 2017 in Nature
Verified
Journal Article
Closed access
AIAustralian Pancreatic Cancer Genome Initiative
Australian Pancreatic Cancer Genome Initiative
ASAldo Scarpa
Aldo Scarpa
DCDavid K. Chang
David K. Chang
Katia NonesKatia Nones
Katia Nones
VCVincenzo Corbo
Vincenzo Corbo
SGSean M. Grimmond
Sean M. Grimmond

1 March 2012 in The Lancet Oncology
Verified
Journal Article
Closed access
HJHeikki Joensuu
Heikki Joensuu
AVAki Vehtari
Aki Vehtari
JRJaakko Riihimäki
Jaakko Riihimäki
TNToshirou Nishida
Toshirou Nishida
SSSonja E Steigen
Sonja E Steigen
Piotr RutkowskiPiotr Rutkowski
Piotr Rutkowski